2月6日,阿斯利康公布了2024年全球业绩:总营收540.73亿美元,同比增加21%,主要靠奥希替尼、达格列净、度伐利尤单抗等拉动,这三个品种的销售额分别为65.8亿美元、77.17亿美元和47.17美元。德曲妥珠单抗销售额达到37.54亿美元,同比增长46%。值得注意的是,阿斯利康2024年中国区收入64.13亿美元,同比增长11%,占据其全球市场份额的12%。已经公布中国区业绩的跨国药企包括...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.